Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Finished Goods (2023 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Finished Goods for 3 consecutive years, with $208195.0 as the latest value for Q2 2025.

  • On a quarterly basis, Finished Goods rose 74.99% to $208195.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $208195.0, a 74.99% increase, with the full-year FY2024 number at $157881.0, down 15.65% from a year prior.
  • Finished Goods was $208195.0 for Q2 2025 at 60 Degrees Pharmaceuticals, up from $143161.0 in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $208195.0 in Q2 2025 to a low of $84449.0 in Q3 2024.
  • A 3-year average of $150890.1 and a median of $156390.0 in 2024 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: decreased 15.65% in 2024, then soared 74.99% in 2025.
  • 60 Degrees Pharmaceuticals' Finished Goods stood at $187182.0 in 2023, then fell by 15.65% to $157881.0 in 2024, then soared by 31.87% to $208195.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Finished Goods are $208195.0 (Q2 2025), $143161.0 (Q1 2025), and $157881.0 (Q4 2024).